TW200503719A - Pyridino [1,2-a] pyrimidin-4-one compounds as anticancer agents - Google Patents

Pyridino [1,2-a] pyrimidin-4-one compounds as anticancer agents

Info

Publication number
TW200503719A
TW200503719A TW093117650A TW93117650A TW200503719A TW 200503719 A TW200503719 A TW 200503719A TW 093117650 A TW093117650 A TW 093117650A TW 93117650 A TW93117650 A TW 93117650A TW 200503719 A TW200503719 A TW 200503719A
Authority
TW
Taiwan
Prior art keywords
pyridino
compounds
pyrimidin
anticancer agents
alone
Prior art date
Application number
TW093117650A
Other languages
English (en)
Inventor
Wei-Bo Wang
Ryan N Constantine
Liana M Lagniton
Sabina Pecchi
Matthew T Burger
Manoj C Desai
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of TW200503719A publication Critical patent/TW200503719A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TW093117650A 2003-06-20 2004-06-18 Pyridino [1,2-a] pyrimidin-4-one compounds as anticancer agents TW200503719A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US48018003P 2003-06-20 2003-06-20

Publications (1)

Publication Number Publication Date
TW200503719A true TW200503719A (en) 2005-02-01

Family

ID=33539266

Family Applications (1)

Application Number Title Priority Date Filing Date
TW093117650A TW200503719A (en) 2003-06-20 2004-06-18 Pyridino [1,2-a] pyrimidin-4-one compounds as anticancer agents

Country Status (15)

Country Link
US (1) US7326711B2 (zh)
EP (1) EP1636225B1 (zh)
JP (1) JP2007520435A (zh)
KR (1) KR20060069356A (zh)
CN (1) CN1809563A (zh)
AT (1) ATE458735T1 (zh)
AU (1) AU2004249730A1 (zh)
CA (1) CA2528771A1 (zh)
DE (1) DE602004025698D1 (zh)
ES (1) ES2339862T3 (zh)
IL (1) IL172192A0 (zh)
MX (1) MXPA05013142A (zh)
PT (1) PT1636225E (zh)
TW (1) TW200503719A (zh)
WO (1) WO2004113335A2 (zh)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4259877B2 (ja) * 2000-12-11 2009-04-30 アムジエン・インコーポレーテツド Ｃｘｃｒ３アンタゴニスト
US6794379B2 (en) * 2001-06-06 2004-09-21 Tularik Inc. CXCR3 antagonists
AU2004218080B2 (en) * 2003-03-07 2008-01-03 Astrazeneca Ab Novel fused heterocycles and uses thereof
WO2006018628A1 (en) * 2003-03-07 2006-02-23 Astrazeneca Ab Enantiomers of selected fused pyrimidones and uses in the treatment and preventi on of cancer
EP1694686A1 (en) * 2003-12-19 2006-08-30 Takeda San Diego, Inc. Kinase inhibitors
CA2556914A1 (en) * 2004-02-25 2005-09-09 La Jolla Pharmaceutical Company Amines and amides for the treatment of diseases
CN1984912A (zh) * 2004-04-06 2007-06-20 希龙公司 有丝分裂驱动蛋白抑制剂
JP2007533753A (ja) * 2004-04-23 2007-11-22 タケダ サン ディエゴ インコーポレイテッド インドール誘導体及びキナーゼ阻害剤としてのその使用
KR20070044458A (ko) * 2004-07-22 2007-04-27 아스트라제네카 아베 암의 예방 및 치료에 유용한 융합 피리미돈
JP2008510734A (ja) * 2004-08-18 2008-04-10 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
US20060041128A1 (en) * 2004-08-18 2006-02-23 Astrazeneca Ab Selected fused heterocyclics and uses thereof
CA2575188A1 (en) * 2004-08-18 2006-02-23 Astrazeneca Ab Enantiomers of selected fused pyrimidones and uses in the treatment and preventi on of cancer
ATE479687T1 (de) 2004-10-15 2010-09-15 Takeda Pharmaceutical Kinaseinhibitoren
GB0428250D0 (en) * 2004-12-23 2005-01-26 Novartis Ag Organic compounds
RU2007142007A (ru) * 2005-04-14 2009-05-20 Новартис Вэксинес Энд Дайэгностикс Инк. (Us) 2-аминохиназолин-5-оны
US7799795B2 (en) 2005-06-27 2010-09-21 Amgen Inc. Aryl nitrile compounds and compositions and their uses in treating inflammatory and related disorders
US8119655B2 (en) * 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
EA200970361A1 (ru) 2006-10-09 2010-02-26 Такеда Фармасьютикал Компани Лимитед Ингибиторы киназы
JP2010505961A (ja) * 2006-10-09 2010-02-25 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
US7820646B2 (en) 2007-01-05 2010-10-26 Novartis Vaccines And Diagnostics, Inc. Cyclized derivatives as Eg-5 inhibitors
BRPI1015135B1 (pt) 2009-06-29 2021-08-03 Incyte Holdings Corporation Pirimidinonas inibidoras de pi3k, composição compreendendo tais compostos, bem como usos dos mesmos
WO2011075643A1 (en) 2009-12-18 2011-06-23 Incyte Corporation Substituted heteroaryl fused derivatives as pi3k inhibitors
EP2558463A1 (en) 2010-04-14 2013-02-20 Incyte Corporation Fused derivatives as i3 inhibitors
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
WO2012087881A1 (en) 2010-12-20 2012-06-28 Incyte Corporation N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
US9108984B2 (en) 2011-03-14 2015-08-18 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
US9126948B2 (en) 2011-03-25 2015-09-08 Incyte Holdings Corporation Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
ES2722524T3 (es) 2011-09-02 2019-08-13 Incyte Holdings Corp Heterociclaminas como inhibidores de pi3k
MX354074B (es) * 2012-02-10 2018-02-12 Ptc Therapeutics Inc Compuestos para tratar la atrofia muscular espinal.
CN104302181B (zh) 2012-03-01 2017-09-15 Ptc医疗公司 用于治疗脊髓性肌萎缩的化合物
EP2828247B1 (en) 2012-03-23 2019-01-16 PTC Therapeutics, Inc. 4h-chromen-4-one derivatives for treating spinal muscular atrophy
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
WO2015105657A1 (en) 2013-12-19 2015-07-16 Ptc Therapeutics, Inc. Methods for modulating the amount of rna transcripts
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
MD3831833T2 (ro) 2015-02-27 2023-04-30 Incyte Holdings Corp Procedee pentru prepararea unui inhibitor PI3K
BR112017021083A2 (pt) * 2015-04-15 2018-07-03 F. Hoffmann-La Roche Ag piridopirimidinonas e seu uso como moduladores do receptor de nmda
US10441570B2 (en) 2015-04-21 2019-10-15 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) Ligands and methods of use thereof
US9988401B2 (en) 2015-05-11 2018-06-05 Incyte Corporation Crystalline forms of a PI3K inhibitor
US9732097B2 (en) 2015-05-11 2017-08-15 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
WO2016184832A1 (en) * 2015-05-20 2016-11-24 F. Hoffmann-La Roche Ag Compounds for treating spinal muscular atrophy
EP3310169B1 (en) 2015-05-30 2023-05-17 PTC Therapeutics, Inc. Methods for modulating rna splicing
CA3119019C (en) 2015-12-10 2024-06-11 Ptc Therapeutics, Inc. Compounds and methods for treating huntington's disease
EP3544435A4 (en) 2016-11-28 2020-11-04 PTC Therapeutics, Inc. RNA SPLICE MODULATION PROCESSES
SG11201911615WA (en) 2017-06-05 2020-01-30 Ptc Therapeutics Inc Compounds for treating huntington's disease
KR20200017476A (ko) 2017-06-14 2020-02-18 피티씨 테라퓨틱스, 인크. Rna 스플라이싱의 변경 방법
US11395822B2 (en) 2017-06-28 2022-07-26 Ptc Therapeutics, Inc. Methods for treating Huntington's disease
BR112019027717A2 (pt) 2017-06-28 2020-07-28 Ptc Therapeutics, Inc. métodos para tratar a doença de huntington
CN108191860B (zh) * 2018-02-12 2019-12-10 中国医科大学 一种HIF-2α小分子抑制剂及其用途
US12103926B2 (en) 2018-03-27 2024-10-01 Ptc Therapeutics, Inc. Compounds for treating huntington's disease
LT3814357T (lt) 2018-06-27 2024-06-25 Ptc Therapeutics, Inc. Heterocikliniai ir heteroarilų junginiai, skirti hantingtono ligos gydymui
US11685746B2 (en) 2018-06-27 2023-06-27 Ptc Therapeutics, Inc. Heteroaryl compounds for treating Huntington's disease

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0702959B1 (en) * 1993-05-31 2001-08-08 Kaken Pharmaceutical Co., Ltd. Cross-linked gelatin gel preparation containing basic fibroblast growth factor
GB2307177A (en) 1995-11-15 1997-05-21 Agrevo Uk Ltd Fungicidal pyridopyrimidines
EP1686120A3 (en) 1999-10-27 2007-05-30 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US6545004B1 (en) * 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
JP4259877B2 (ja) 2000-12-11 2009-04-30 アムジエン・インコーポレーテツド Ｃｘｃｒ３アンタゴニスト
US7108972B2 (en) * 2001-02-21 2006-09-19 Curagen Corporation Proteins, polynucleotides encoding them and methods of using the same
US7060705B2 (en) * 2001-11-07 2006-06-13 Merck & Co., Inc. Mitotic kinesin inhibitors
CA2468156A1 (en) * 2001-12-06 2003-06-19 Merck & Co., Inc. Azolopyrimidinone compounds and their use
US7244723B2 (en) 2001-12-06 2007-07-17 Merck & Co., Inc. Substituted furopyrimidinones as a mitotic kinesin inhibitors
US20070149500A1 (en) * 2003-01-17 2007-06-28 Han-Jie Zhou Compounds, compositions, and methods

Also Published As

Publication number Publication date
AU2004249730A1 (en) 2004-12-29
EP1636225B1 (en) 2010-02-24
ATE458735T1 (de) 2010-03-15
EP1636225A2 (en) 2006-03-22
WO2004113335A3 (en) 2005-03-24
US7326711B2 (en) 2008-02-05
MXPA05013142A (es) 2006-03-17
CA2528771A1 (en) 2004-12-29
CN1809563A (zh) 2006-07-26
JP2007520435A (ja) 2007-07-26
WO2004113335A2 (en) 2004-12-29
IL172192A0 (en) 2006-04-10
KR20060069356A (ko) 2006-06-21
PT1636225E (pt) 2010-05-03
ES2339862T3 (es) 2010-05-26
US20050085490A1 (en) 2005-04-21
DE602004025698D1 (de) 2010-04-08

Similar Documents

Publication Publication Date Title
TW200503719A (en) Pyridino [1,2-a] pyrimidin-4-one compounds as anticancer agents
IL175714A0 (en) Quinazolinone compounds as anticancer agents
TW200505454A (en) Heteroaryl-fused pyrimidinyl compounds as anticancer agents
WO2005070930A3 (en) Tetrahydrocarboline compounds as anticancer agents
WO2004006859A3 (en) Platinum compound
TW200728304A (en) 2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-ones
IL267381A (en) A pharmaceutical preparation containing dextromethorphan and quinidine for the treatment of nervous disorders
TW200718689A (en) 2-Amino-quinazolin-5-ones
PL377821A1 (pl) 2,4,6-tripodstawione pirymidyny jako inhibitory kinazy fosfatydyloinozytolu (PI) 3 i ich zastosowanie w leczeniu nowotworu
BG108268A (en) Pyrazolopyrimidines as therapeutic agents
WO2004087713A8 (en) Salts of tricyclic inhibitors of poly(adp-ribose) polymerases
HK1065483A1 (en) 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives
EP1259240B8 (en) Agents, such as nicotinamide or cadpr for the treatment of skin disorders
WO2005004808A3 (en) TETRACYCLIC COMPOUNDS AS c-MET INHIBITORS
UA93522C2 (en) 2-amino-7,8-dihydro-6h-pyrido[4,3-d] pyrimidin-5-ones
GEP20105095B (en) Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents
PL1718651T3 (pl) Pochodne 7H-pirolopirymidyny
WO2002076930A3 (en) Substituted diarylureas as stimulators for fas-mediated apoptosis
MXPA05008490A (es) Combinaciones que contienen imidazopiridinas y su uso en el tratamiento de enfermedades gastrointestinales inflamatorias.